Evidence is mounting that links insulin deficiency and insulin resistance to mediation of Alzheimer disease-type neurodegeneration. Get the highlights in these 9 slides.
Do You Speak DPP-4I?
There are 10 FDA-approved DPP-4 inhibitors--single agents and combination products. Do you speak their language? Find out with these 5 questions.
Diabetes Quizlet: 3 Quick Questions
Spot check your memory for these disease details.
Diabetes Drug Quiz: Do You Know Your Generics vs Trades?
Trade names often mask the essential nature of a medication, but some of the new agents that treat type 2 diabetes take it to a new level. Here, 5 chances to see what you know.
SGLT2 Inhibitor Lowers Serum Uric Acid
A new post-hoc analysis suggests that what’s good for hyperglycemia may also be good for hyperuricemia.
Albiglutide Effective in Triple Therapy for Uncontrolled Type 2 Diabetes
In obese patients with type 2 diabetes uncontrolled by lifestyle and two oral agents, albiglutide significantly lowered A1c as part of 3-drug therapy.
Dulaglutide Bests Sitagliptin: Review of AWARD-5
At 52 weeks, dulaglutide resulted in significantly greater reductions in HbA1c, FPG, and weight compared with the DPP-4 inhibitor sitagliptin.
Comorbid Curiousity: Which One Doesn't Pertain?
Conditions associated with long-term diabetes affect myriad organs and systems. Which one of these comorbidities is not associated with the disease?
Could Alzheimer Disease Be Diabetes Type 3?
10 New FDA-Approved Endocrinology Drugs
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
By clicking Accept, you agree to become a member of the UBM Medica Community.